Rua Life Sciences Share Discussion Threads

[marmiesz] 21/11/2024 12:34

Cfb, I might be misreading this, but the latest update stated the group had secured £1.5M in revenue before Abiss. Once they include the Abiss revenue, then the group as whole had made a £400k pre tax profit. Either way, I do see this as undervalued by some margin. I have been drip buying recently and I think I'll continue to do so. Not a trader so I see this as an investment,Marmie

[cfb2] 21/11/2024 12:03

Marmie, I have pondered a similar question. I'll put myself up as a straw man so that some of the people invested here can correct me.

RUA's profit was from the £900k from purchasing Abiss. From what I can discover about Abiss this was a one off but I am struggling to find out what their long term contribution to RUA might be as they are hidden within IPSAS SAS. Without Abiss, RUA are losing around £1m a year and everything BB has touched has turned to sh*t.

I have looked at legal/financial liabilities pending for Abiss to justify the low liquidator price but can't find any.

[marmiesz] 21/11/2024 08:54

Hi, I'm looking into RUA and I am somewhat confused. They have £3.5M cash; made £400k pre tax profit and due to increase this. Yet the share price is sitting on a market cap of about £7M. Why?Thanks,Marmie

[z1co] 20/11/2024 16:22

Another large buy of 101,433 @ 12.0108p gone through

[z1co] 20/11/2024 15:17

Gone NT to buy @ 12p , can't even buy 15,000 !

[z1co] 20/11/2024 15:13

The 150,000 trade shown as a sell by advfn is actually a BUY from 2 hours ago.

[z1co] 20/11/2024 14:50

It's currently NT to buy and has been NT since the 6000 buy @ 11p

[z1co] 20/11/2024 14:48

Added to my holding @ 10.996p and 11.00p

[cocker] 17/11/2024 14:35

The man without a single follower has spoken!. Well pipe up when the Jock actually presents shareholders with good news , rather than updates of failure and the begging bowl

[lufc11] 14/11/2024 15:27

I'm looking forward to the outlook for the current when the company reports it's interim results next month.

This year H2 will be very strong in comparison with the first half.The £400,000 contract announced in July has expanded to around £700,000 and is to be delivered in H2

The company will also ensure the €1m order backlog for Abiss Group caused by supply chain issues relating to packaging components (now resolved) is dispatched to customers during the 2nd half.

[chatchat] 14/11/2024 14:15

and not all the sells are sells

[chatchat] 14/11/2024 13:35

Agree - I have added too

[lufc11] 14/11/2024 13:00

I've been buying,excellent value at this over sold level.

[z1co] 04/11/2024 17:31

Thanks rivaldo

[rivaldo] 04/11/2024 15:37

Cavendish are waiting for the due diligence on Aniss to be concluded before updating their forecasts.

They expect Abiss to add £2m to revenues over a full 12 month period.

[z1co] 02/11/2024 08:43

Prior to the Abiss acquisition Cavendish was forecasting £3.3m for year ending March 2025.A minimum of £4m must be on the cards.

Anyone have the latest Cavendish forecasts ?

[z1co] 01/11/2024 07:55

Posted by NickE on lse:

Good find Jimzi, and often with smaller medical device companies the P/E ratio is usually higher than that of established players. As you say we can't necessarily apply a P/E of around 64 especially as U.S. companies have a higher P/E assigned than UK stocks. Also, the 900k 'fair value' is I assume a temporary boost to the move to profitability although ABISS will accelerate the move to profitability. Regardless, markets look ahead and a value for a high growth medical device company moving to profitability with other increasingly 'oven ready' blue sky products should be a multiple of where we are now.

Following on from the Aortech shareholder base, RUA's history has mainly been in the blue sky sector so value investors probably don't have it on their radar. It's almost as if the stock is punished for being both blue sky and a value play.

It may be that the 50p plus valuation the stock probably deserves will only come with full or partial acquisition and on that topic some very astute posts from IntraVnus.

RUA do tend to drop hints and when they spoke about doubling revenues they didn't allude to the bargain £80k acquisition but the clue was there. Maybe "the Company has changed its financial year end to better guide business planning and international business unit assimilation" is flagging up another acquisition but this time it's RUA itself.

I wonder how that would pan out? They would be interested in contract manufacturing and Elast-Eon but would Coloplast have any need for Rua Vascular and Structural Heart? Unless of course they are looking to expand into long-term implants or soft tissue repair. This quarter could get interesting.

[bsg] 31/10/2024 15:06

A buy is a buy as they say.